Gateway Investment Advisers’s Jazz Pharmaceuticals JAZZ Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $994K | Buy |
4,123
+2,649
| +180% | +$580K | 0.01% | 444 |
|
|
2026
Q1 | $279K | Buy |
+1,474
| New | +$258K | ﹤0.01% | 632 |
|
|
2024
Q4 | – | Sell |
-2,007
| Closed | -$224K | – | 506 |
|
|
2024
Q3 | $224K | Sell |
2,007
-123
| -6% | -$13.5K | ﹤0.01% | 489 |
|
|
2024
Q2 | $227K | Sell |
2,130
-18
| -0.8% | -$1.98K | ﹤0.01% | 479 |
|
|
2024
Q1 | $259K | Sell |
2,148
-42
| -2% | -$5.14K | ﹤0.01% | 461 |
|
|
2023
Q4 | $269K | Sell |
2,190
-12,816
| -85% | -$1.6M | ﹤0.01% | 449 |
|
|
2023
Q3 | $1.94M | Sell |
15,006
-17
| -0.1% | -$2.27K | 0.02% | 269 |
|
|
2023
Q2 | $1.86M | Sell |
15,023
-6
| -0% | -$807 | 0.02% | 279 |
|
|
2023
Q1 | $2.2M | Sell |
15,029
-248
| -2% | -$36.7K | 0.03% | 284 |
|
|
2022
Q4 | $2.43M | Buy |
15,277
+167
| +1% | +$24.5K | 0.03% | 293 |
|
|
2022
Q3 | $2.01M | Sell |
15,110
-167
| -1% | -$25.4K | 0.03% | 316 |
|
|
2022
Q2 | $2.38M | Hold |
15,277
| – | – | 0.03% | 304 |
|
|
2022
Q1 | $2.38M | Buy |
15,277
+64
| +0.4% | +$9.29K | 0.02% | 323 |
|
|
2021
Q4 | $1.94M | Buy |
15,213
+13,240
| +671% | +$1.74M | 0.02% | 316 |
|
|
2021
Q3 | $257K | Buy |
1,973
+5
| +0.3% | +$755 | ﹤0.01% | 494 |
|
|
2021
Q2 | $350K | Hold |
1,968
| – | – | ﹤0.01% | 463 |
|
|
2021
Q1 | $323K | Buy |
1,968
+49
| +3% | +$8.06K | ﹤0.01% | 468 |
|
|
2020
Q4 | $317K | Sell |
1,919
-18
| -0.9% | -$2.68K | ﹤0.01% | 464 |
|
|
2020
Q3 | $276K | Sell |
1,937
-20,613
| -91% | -$2.56M | ﹤0.01% | 463 |
|
|
2020
Q2 | $2.49M | Sell |
22,550
-3,869
| -15% | -$428K | 0.03% | 299 |
|
|
2020
Q1 | $2.63M | Sell |
26,419
-23
| -0.1% | -$2.97K | 0.03% | 285 |
|
|
2019
Q4 | $3.95M | Sell |
26,442
-1,911
| -7% | -$260K | 0.04% | 280 |
|
|
2019
Q3 | $3.63M | Buy |
28,353
+44
| +0.2% | +$5.9K | 0.04% | 304 |
|
|
2019
Q2 | $4.04M | Sell |
28,309
-11
| -0% | -$1.48K | 0.04% | 296 |
|
|
2019
Q1 | $4.05M | Sell |
28,320
-537
| -2% | -$70K | 0.04% | 295 |
|
|
2018
Q4 | $3.58M | Buy |
28,857
+875
| +3% | +$130K | 0.03% | 307 |
|
|
2018
Q3 | $4.71M | Sell |
27,982
-149
| -0.5% | -$25.6K | 0.04% | 285 |
|
|
2018
Q2 | $4.85M | Sell |
28,131
-11,295
| -29% | -$1.85M | 0.04% | 280 |
|
|
2018
Q1 | $5.95M | Sell |
39,426
-14,598
| -27% | -$2.14M | 0.05% | 255 |
|
|
2017
Q4 | $7.27M | Buy |
54,024
+22,253
| +70% | +$3.09M | 0.06% | 236 |
|
|
2017
Q3 | $4.65M | Buy |
31,771
+11,972
| +60% | +$1.81M | 0.04% | 292 |
|
|
2017
Q2 | $3.08M | Sell |
19,799
-53,596
| -73% | -$8.2M | 0.03% | 334 |
|
|
2017
Q1 | $10.7M | Buy |
73,395
+8,418
| +13% | +$1.1M | 0.1% | 190 |
|
|
2016
Q4 | $7.08M | Buy |
64,977
+774
| +1% | +$86.2K | 0.07% | 226 |
|
|
2016
Q3 | $7.8M | Buy |
64,203
+30,097
| +88% | +$4.06M | 0.07% | 224 |
|
|
2016
Q2 | $4.82M | Buy |
+34,106
| New | +$5.03M | 0.04% | 272 |
|
Other funds holding JAZZ
Gateway Investment Advisers's JAZZ Position: Q2 2026 in Review
Gateway Investment Advisers increased its Jazz Pharmaceuticals (JAZZ) stake by 180% in Q2 2026, buying an estimated $580K and bringing the position to 4,123 shares worth $994K. The position accounts for 0.01% of the portfolio, ranked #444.
Gateway Investment Advisers first reported a position in JAZZ in Q2 2016 and has held it in 36 quarters since. The position peaked at $10.7M in Q1 2017. 641 funds tracked by Wall St. Rank hold JAZZ as of Q2 2026.
- Gateway Investment Advisers held 4,123 shares of Jazz Pharmaceuticals worth $994K as of Q2 2026.
- Gateway Investment Advisers bought 2,649 Jazz Pharmaceuticals shares in Q2 2026, an estimated $580K.
- Jazz Pharmaceuticals made up 0.01% of Gateway Investment Advisers's portfolio in Q2 2026, its #444 holding.
- Gateway Investment Advisers first reported a position in Jazz Pharmaceuticals in Q2 2016 and has held it in 36 quarters since.
- Gateway Investment Advisers's Jazz Pharmaceuticals position peaked at $10.7M in Q1 2017.
- 641 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q2 2026.
Based on Gateway Investment Advisers's 13F filing for Q2 2026, filed 20 Jul 2026.